Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III

Inclusion Criteria: * Patient must have a histologically proven TNM stage II or III adenocarcinoma of colon or rectum. * Patient must received curative surgical with cancer free margin. * Patients must have a performance status of 0,1, or 2. * Patients must have an absolute neutrophil count of greater than or equal to 1500/ml, platelet count greater than or equal to 100,000/ml, and total serum bilirubin equal or less than the institution's upper limit or normal range. * Patients must have fully recovered from any effects of surgery. * Patients must provide a signed consent to participate in the study. Age: •18 and over Performance status: •WHO 0-2 Life expectancy: •Not specified Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST/ALT no greater than 1.5 times ULN Renal: •Creatinine clearance greater than 30 mL/min Cardiovascular: More than 12 months since prior and no active clinically significant cardiovascular disease, including any of the following: * Cerebrovascular accident * Myocardial infarction * Unstable angina * New York Heart Association class II-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Uncontrolled hypertension (i.e., blood pressure \> 150/100 mm Hg) Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No active peptic ulcer or gastrointestinal bleeding within the past year * No inflammatory bowel disease * No other malignancy within the past 10 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer Exclusion Criteria: * Patients with a proven history of peptic ulcer disease or gastroesophageal reflux. * Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs. * Patients who have received prior chemotherapy for colorectal cancer except for patients relapsing more than 6 months after completion of adjuvant chemotherapy. * History of other malignancy, except for cancers that have been treated with a curative intent and patient is without evidence of active disease. * Unresolved bacterial infection requiring treatment with antibiotics. * Pregnant or lactating women may not participate in the study. Women/men of reproductive age group may not participate unless they have agreed to use an effective method of contraception. * Patients who have allergy to any of the study drugs. * Patients known to have HIV-1 virus infection because of the undetermined effect of this chemotherapy regimen in patients with HIV-1 and the potential for serious interaction with anti-HIV medications. * Gilbert's disease. * Lack of physical integrity of the upper gastrointestinal tract. Inability to swallow tablets or those who have malabsorption syndrome. * Other serious concurrent infection * Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction within the last 12 months.